Bildkälla: Stockfoto

Ascelia Pharma: Time for take-off - Redeye

Ascelia’s Q1 result was minor compared to the recent SPARKLE success. Ascelia is preparing for submission by mid-2025, and Ascelia’s cost base was contained. Our Base Case is SEK 17 (Bull SEK 45 and Bear SEK 6).

Ascelia’s Q1 result was minor compared to the recent SPARKLE success. Ascelia is preparing for submission by mid-2025, and Ascelia’s cost base was contained. Our Base Case is SEK 17 (Bull SEK 45 and Bear SEK 6).
Börsvärldens nyhetsbrev
ANNONSER